Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atilotrelvir/Ritonavir in Mild to Moderate COVID-19
NCT05656443Phase 3Completed
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
- Start
- Dec 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Atilotrelvir + Ritonavir with Placebo (2 arms). Primary endpoint: Time to sustained clinical recovery of 11 COVID-19 symptoms at Day 28. Started Dec 2022; status: completed.
02
Drugs
atilotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05656443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05656443.